Pharmaceutical company GlaxoSmithKline and Vir Biotechnology have reached their primary end point with a phase III clinical study of intramuscular administration of sotrovimab.
The study showed that intramuscular administration is not inferior to intravenous administration for early treatment of COVID-19 in high-risk adults and adolescents. The companies noted that the study was conducted at the height of the delta variable prevalence in Florida.
“We designed sotrovimab to withstand the variants we expected, and this data shows that sotrovimab, given intravenously or intramuscularly, will prove valuable in the fight against COVID-19 once approved,” Vir CEO George Scangos said.
Shares of UK-listed GlaxoSmithKline rose 0.31 percent at times to 15.94 pounds, while shares of Fair rose 1.94 percent in US trading to $32.42.
London (Dow Jones)
Sylvia Plath writes for Social Post News, covering news, politics, business, technology, sport, entertainment, and lifestyle. She focuses on clear, reliable reporting and useful information, helping readers stay informed about current events, emerging trends, and stories that matter.
More Stories
Colorado Springs Could Gain Second Stop on Colorado’s Front Range Passenger Rail Line Under New Draft Plan
Amazon Prime Day Deals Still Available: More Than 130 Discounts Remain on Apple, Oura, Sony and Other Top Brands
Wealthy families take more risks when it comes to money.